Filtered By:
Cancer: Oral Cancer
Vaccination: Cervical Cancer Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 40 results found since Jan 2013.
Cross-neutralizing protection of vaginal and oral mucosa from HPV challenge by vaccination in a mouse model
Vaccine. 2023 Jun 1:S0264-410X(23)00618-7. doi: 10.1016/j.vaccine.2023.05.057. Online ahead of print.ABSTRACTThe species and tissue specificities of HPV (human papillomavirus) for human infection and disease complicates the process of prophylactic vaccine development in animal models. HPV pseudoviruses (PsV) that carry only a reporter plasmid have been utilized in vivo to demonstrate cell internalization in mouse mucosal epithelium. The current study sought to expand the application of this HPV PsV challenge model with both oral and vaginal inoculation and to demonstrate its utility for testing vaccine-mediated dual-site i...
Source: Vaccine - June 3, 2023 Category: Allergy & Immunology Authors: Chelsea Sanders Rebecca L Matthews Sayyed Hamid Zarkesh Esfahani Nazneen Khan Nimit L Patel Joseph D Kalen Reinhard Kirnbauer Richard B Roden Simone Difilippantonio Ligia A Pinto Robert H Shoemaker Jason D Marshall Source Type: research
Self-reported HPV vaccination and vaccination record linkage in the Australian Oral Diversity Study
CONCLUSION: We found that the correlation between self-reported Gardasil® vaccination and the AIR records were very good, with high sensitivity and specificity.PMID:37256380 | DOI:10.1007/s10552-023-01729-4
Source: Cancer Control - May 31, 2023 Category: Cancer & Oncology Authors: Annika Antonsson Source Type: research
Risk Factors and Trends for HPV-Associated Subsequent Malignant Neoplasms among Adolescent and Young Adult Cancer Survivors
CONCLUSIONS: HPV-SMN in AYA survivors are driven by oropharyngeal cancers despite temporal declines in oropharyngeal-SMN. Hispanic survivors are at risk for cervical-SMN relative to the general population.IMPACT: Encouraging HPV vaccination and cervical and oral cancer screenings may reduce HPV-SMN burden among AYA survivors.PMID:37071501 | DOI:10.1158/1055-9965.EPI-22-0826
Source: Cancer Control - April 18, 2023 Category: Cancer & Oncology Authors: Judy Y Ou Natalie Bennion Kellee Parker Douglas Fair Heidi A Hanson Deanna Kepka Echo L Warner Joemy M Ramsay Heydon K Kaddas Anne C Kirchhoff Source Type: research
SOGC Guideline Retirement Notice No. 3
J Obstet Gynaecol Can. 2022 Nov;44(11):1226-1236. doi: 10.1016/j.jogc.2022.09.005.ABSTRACTThese documents have been archived because they contain outdated information. They should not be consulted for clinical use, but for historical research only. Please visit the journal website for the most recent guidelines. Prenatal Screening for Fetal Aneuploidy [J Obstet Gynaecol Can 29 (2007) 146-161] AUTHORS Anne Summers, MD, North York, ON Sylvie Langlois, MD, Vancouver, BC Phil Wyatt, MD, PhD, Toronto, ON R. Douglas Wilson, MD, Philadelphia, PA A Report on Best Practices for Returning Birth to Rural and Remote Aboriginal Communi...
Source: Rural Remote Health - November 21, 2022 Category: Rural Health Source Type: research
The Evolving Epidemiology of Oral Cavity and Oropharyngeal Cancers
This study, the largest at the time, introduced several novel concepts in oropharyngeal cancer epidemiology that remain relevant today-etiologic heterogeneity, statistical interaction effects, adjusted attributable fractions, and disparities by sex and race/ethnicity. Perhaps the most significant recognition in the field since 1988 is the etiologic association of human papillomavirus (HPV, primarily HPV16) with cancers arising in the oropharynx. Today, more than 80% of oropharyngeal cancers in the United States are caused by HPV while only approximately 3% of oral cavity cancers are caused by HPV. This etiologic heterogene...
Source: Cancer Control - August 16, 2022 Category: Cancer & Oncology Authors: Anil K Chaturvedi Neal D Freedman Christian C Abnet Source Type: research
Double Positivity for HPV DNA/P16(INK4a) Does Not Influence Survival of Patients With Oral Squamous Cell Carcinoma
CONCLUSION: In contrast to oropharyngeal cancer, the prevalence of HPV in OSCC is low and the presence of HPV does not influence survival outcomes. Hence, there is no evidence to support a parallel transfer of therapy regimen for HPV-positive OPC to OSCC, in terms of therapy de-escalation and/or vaccination.PMID:34732426 | DOI:10.21873/anticanres.15369
Source: Cell Research - November 4, 2021 Category: Cytology Authors: Ubai Alsharif Marvin Hofmann Maximilian Gebhard Lars Tharun Dirk Rades Peter Sieg Samer G Hakim Source Type: research
Landscape assessment for gender neutral human papillomavirus vaccination recommendations including head and neck cancer burden data
CONCLUSION: The burden of HPV-related HNC in the general male population has been recognized by several Heatlth Technology Assessment (HTA) agencies and National Immunization Technical Advisory Groups (NITAGs) when evaluating HPV GNV programs. The assessments identified on GNV programs strongly indicate a cost-effective clinical benefit. Nevertheless, the epidemiological burden of HNC may have been underestimated in some countries due to limited data. Further research is crucial to obtain more robust data that will help address the information gap in epidemiological and economic burden of HPV-associated HNC in men.PMID:344...
Source: Vaccine - August 28, 2021 Category: Allergy & Immunology Authors: Edith Morais Nadia El Mouaddin Susanne Schuurman Atish De Source Type: research
Human papillomavirus (HPV) in pregnancy - An update
Eur J Obstet Gynecol Reprod Biol. 2021 Jul 31;264:340-348. doi: 10.1016/j.ejogrb.2021.07.053. Online ahead of print.ABSTRACTHuman papilloma viruses (HPV) are small epitheliotropic DNA viruses, of which there are 200 genotypes, 40 of which are known to cause genital infections and are also oncogenic. HPV is the most common sexually transmitted infection. Clinical features vary from asymptomatic (identified at routine cervical cancer screening) to large lesions on the vulva, vagina, cervix and some extragenital sites. Its prevalence in pregnancy varies from 5.5% to 65% depending on age, geography and gestational age (increas...
Source: Reproductive Biology - August 13, 2021 Category: Reproduction Medicine Authors: Victor N Chilaka Osric B Navti Mariam Al Beloushi Badredeen Ahmed Justin C Konje Source Type: research
The impact of HPV vaccination on the prevention of oropharyngeal cancer: A scoping review
CONCLUSIONS: There is evidence to suggest that HPV vaccination reduces oral HPV infection and decreases the incidence of HPV-associated OPC. There is substantial need for further research which directly examines the relationship between HPV vaccination status and subsequent OPC development.PMID:34304398 | DOI:10.1922/CDH_00072Kaczmarczyk08
Source: Community Dental Health - July 25, 2021 Category: Dentistry Authors: K H Kaczmarczyk H Yusuf Source Type: research
